Cormedix Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Cormedix Inc. on January 14, 2011. The report details material definitive agreements and changes to compensatory arrangements for certain officers and directors, effective January 1, 2011.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. The document focuses exclusively on executive and director compensation adjustments.
Material Changes
- CEO Compensation: John C. Houghton's annual base salary was increased to $350,000. His discretionary bonus potential was increased to up to 40% of his annual base salary upon achieving specific milestones.
- CFO Compensation: Brian Lenz's annual base salary was increased to $250,000. His annual guaranteed bonus was eliminated.
- Director Compensation: The Board adopted a revised policy increasing the annual retainer for non-employee directors to $20,000 (Chairman: $30,000). Non-employee directors will receive an annual option grant for 30,000 shares vesting on the first anniversary. New directors receive an initial grant of 30,000 shares vesting in three equal tranches over two years.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or management commentary regarding business operations. No specific risks or contingencies were disclosed in this report beyond the standard incorporation of the full employment agreement texts.
Investor Verification Checklist
- Review the full text of the Houghton Amendment (Exhibit 10.1) to understand the specific "Milestones" required for the CEO's discretionary bonus.
- Review the full text of the Lenz Amendment (Exhibit 10.2) to confirm the terms regarding the elimination of the guaranteed bonus.
- Verify the total number of shares reserved for the new director option grants and their impact on dilution.
- Confirm the Company's current cash position to assess the ability to fund the increased fixed salary obligations.